ASCO 2019: Xtandi bumps up three-year prostate cancer survival rates

An interim analysis of the Phase III ENZAMET trial has found that 80% of men with metastatic hormone-sensitive prostate cancer who received Xtandi (enzalutamide) along with standard-of-care treatment were alive at three years.

This compares to 72% of men who received other non-steroidal antiandrogens along with standard treatment, according to the findings, which were presented at the ASCO meeting this weekend.

The 80% figure came in those taking Xtandi along with testosterone suppression, with or without early docetaxel, a chemotherapy drug.